APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Duchenne Muscular Dystrophy (DMD)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis and Forecast 2026-2032

2 January 2026190 pages

Choose your research edition.

Industry ResearchDrugs for Duchenne Muscular Dystrophy (DMD) Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Drugs for Duchenne Muscular Dystrophy (DMD) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Drugs for Duchenne Muscular Dystrophy (DMD) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drugs for Duchenne Muscular Dystrophy (DMD) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drugs for Duchenne Muscular Dystrophy (DMD) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drugs for Duchenne Muscular Dystrophy (DMD) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Drugs for Duchenne Muscular Dystrophy (DMD) include Bristol-Myers Squibb, Italfarmaco, PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics, WaVe life Science and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drugs for Duchenne Muscular Dystrophy (DMD), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drugs for Duchenne Muscular Dystrophy (DMD), also provides the revenue of main regions and countries. Of the upcoming market potential for Drugs for Duchenne Muscular Dystrophy (DMD), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for Duchenne Muscular Dystrophy (DMD) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drugs for Duchenne Muscular Dystrophy (DMD) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drugs for Duchenne Muscular Dystrophy (DMD) revenue, projected growth trends, production technology, application and end-user industry.

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Company

Bristol-Myers Squibb

Italfarmaco

PTC Therapeutics

Santhera Pharmaceuticals

Sarepta Therapeutics

WaVe life Science

Pfizer

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type

Eteplirsen

Deflazacort

Ataluren

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application

Home Care

Hospitals

Clinics

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Duchenne Muscular Dystrophy (DMD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Duchenne Muscular Dystrophy (DMD) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Duchenne Muscular Dystrophy (DMD).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drugs for Duchenne Muscular Dystrophy (DMD) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drugs for Duchenne Muscular Dystrophy (DMD) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Duchenne Muscular Dystrophy (DMD) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Eteplirsen Major Player Table 3. Deflazacort Major Player Table 4. Ataluren Major Player Table 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Home Care Major Player Table 7. Hospitals Major Player Table 8. Clinics Major Player Table 9. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Trends Table 10. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Drivers Table 11. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Opportunities and Challenges Table 12. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Restraints Table 13. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region (2021-2026) Table 16. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region (2027-2032) Table 18. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Players (2021-2026) Table 20. Global Drugs for Duchenne Muscular Dystrophy (DMD) Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Drugs for Duchenne Muscular Dystrophy (DMD) Key Players Headquarters & Area Served Table 22. Global Drugs for Duchenne Muscular Dystrophy (DMD) Players, Product Type & Application Table 23. Global Drugs for Duchenne Muscular Dystrophy (DMD) Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Drugs for Duchenne Muscular Dystrophy (DMD) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2021-2026) Table 30. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2027-2032) Table 31. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2021-2026) Table 35. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2027-2032) Table 36. Bristol-Myers Squibb Company Information Table 37. Bristol-Myers Squibb Business Overview Table 38. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 40. Bristol-Myers Squibb Recent Development Table 41. Italfarmaco Company Information Table 42. Italfarmaco Business Overview Table 43. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 45. Italfarmaco Recent Development Table 46. PTC Therapeutics Company Information Table 47. PTC Therapeutics Business Overview Table 48. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 50. PTC Therapeutics Recent Development Table 51. Santhera Pharmaceuticals Company Information Table 52. Santhera Pharmaceuticals Business Overview Table 53. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 55. Santhera Pharmaceuticals Recent Development Table 56. Sarepta Therapeutics Company Information Table 57. Sarepta Therapeutics Business Overview Table 58. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 60. Sarepta Therapeutics Recent Development Table 61. WaVe life Science Company Information Table 62. WaVe life Science Business Overview Table 63. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 65. WaVe life Science Recent Development Table 66. Pfizer Company Information Table 67. Pfizer Business Overview Table 68. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 70. Pfizer Recent Development Table 71. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026) & (US$ Million) Table 72. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2027-2032) & (US$ Million) Table 73. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026) & (US$ Million) Table 74. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2027-2032) & (US$ Million) Table 75. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 76. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021-2026) & (US$ Million) Table 77. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (US$ Million) & (2027-2032) Table 78. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026) & (US$ Million) Table 79. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2027-2032) & (US$ Million) Table 80. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026) & (US$ Million) Table 81. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2027-2032) & (US$ Million) Table 82. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 83. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021-2026) & (US$ Million) Table 84. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (US$ Million) & (2027-2032) Table 85. China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026) & (US$ Million) Table 86. China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2027-2032) & (US$ Million) Table 87. China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026) & (US$ Million) Table 88. China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2027-2032) & (US$ Million) Table 89. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026) & (US$ Million) Table 90. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2027-2032) & (US$ Million) Table 91. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026) & (US$ Million) Table 92. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2027-2032) & (US$ Million) Table 93. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 94. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Region (US$ Million) & (2021-2026) Table 95. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Region (US$ Million) & (2027-2032) Table 96. SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026) & (US$ Million) Table 97. SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2027-2032) & (US$ Million) Table 98. SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026) & (US$ Million) Table 99. SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2027-2032) & (US$ Million) Table 100. SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021-2026) & (US$ Million) Table 102. SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (US$ Million) & (2027-2032) Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Drugs for Duchenne Muscular Dystrophy (DMD) Image Figure 2. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Eteplirsen Image Figure 5. Deflazacort Image Figure 6. Ataluren Image Figure 7. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share 2021 VS 2025 VS 2032 Figure 9. Home Care Image Figure 10. Hospitals Image Figure 11. Clinics Image Figure 12. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (US$ Million) & (2021-2032) Figure 13. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Drugs for Duchenne Muscular Dystrophy (DMD) Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2021-2032) Figure 20. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2021-2032) Figure 23. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Type (2021-2032) Figure 25. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Application (2021-2032) Figure 26. North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Country (2021-2032) Figure 27. United States Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Type (2021-2032) Figure 32. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Application (2021-2032) Figure 33. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Country (2021-2032) Figure 34. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Type (2021-2032) Figure 44. China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Application (2021-2032) Figure 45. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Type (2021-2032) Figure 47. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Application (2021-2032) Figure 48. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Region (2021-2032) Figure 49. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Type (2021-2032) Figure 57. SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Application (2021-2032) Figure 58. SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Country (2021-2032) Figure 59. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Eteplirsen
  • Deflazacort
  • Ataluren
Applications
  • Home Care
  • Hospitals
  • Clinics
Companies covered
  • Bristol-Myers Squibb
  • Italfarmaco
  • PTC Therapeutics
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics
  • WaVe life Science
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drugs for Duchenne Muscular Dystrophy (DMD) Market by Type
  3. 1.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Eteplirsen
  5. 1.2.3 Deflazacort
  6. 1.2.4 Ataluren
  7. 1.3 Drugs for Duchenne Muscular Dystrophy (DMD) Market by Application
  8. 1.3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Home Care
  10. 1.3.3 Hospitals
  11. 1.3.4 Clinics
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Dynamics
  1. 2.1 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Trends
  2. 2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Drivers
  3. 2.3 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Opportunities and Challenges
  4. 2.4 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Perspective (2021-2032)
  2. 3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Growth Trends by Region
  3. 3.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2021-2026)
  5. 3.2.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Players
  2. 4.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Players (2021-2026)
  3. 4.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Key Players Headquarters & Area Served
  7. 4.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Players, Product Type & Application
  8. 4.5 Global Drugs for Duchenne Muscular Dystrophy (DMD) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market CR5 and HHI
  11. 4.6.3 2025 Drugs for Duchenne Muscular Dystrophy (DMD) Tier 1, Tier 2, and Tier 3
5 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
  1. 5.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2032)
  3. 5.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2021-2032)
6 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
  1. 6.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2032)
  3. 6.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bristol-Myers Squibb
  2. 7.1.1 Bristol-Myers Squibb Company Information
  3. 7.1.2 Bristol-Myers Squibb Business Overview
  4. 7.1.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  6. 7.1.5 Bristol-Myers Squibb Recent Developments
  7. 7.2 Italfarmaco
  8. 7.2.1 Italfarmaco Company Information
  9. 7.2.2 Italfarmaco Business Overview
  10. 7.2.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  12. 7.2.5 Italfarmaco Recent Developments
  13. 7.3 PTC Therapeutics
  14. 7.3.1 PTC Therapeutics Company Information
  15. 7.3.2 PTC Therapeutics Business Overview
  16. 7.3.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  18. 7.3.5 PTC Therapeutics Recent Developments
  19. 7.4 Santhera Pharmaceuticals
  20. 7.4.1 Santhera Pharmaceuticals Company Information
  21. 7.4.2 Santhera Pharmaceuticals Business Overview
  22. 7.4.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  24. 7.4.5 Santhera Pharmaceuticals Recent Developments
  25. 7.5 Sarepta Therapeutics
  26. 7.5.1 Sarepta Therapeutics Company Information
  27. 7.5.2 Sarepta Therapeutics Business Overview
  28. 7.5.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  30. 7.5.5 Sarepta Therapeutics Recent Developments
  31. 7.6 WaVe life Science
  32. 7.6.1 WaVe life Science Company Information
  33. 7.6.2 WaVe life Science Business Overview
  34. 7.6.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  36. 7.6.5 WaVe life Science Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
8 North America
  1. 8.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (2021-2032)
  2. 8.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2032)
  3. 8.2.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026)
  4. 8.2.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2027-2032)
  5. 8.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Type (2021-2032)
  6. 8.4 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2032)
  7. 8.4.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026)
  8. 8.4.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2027-2032)
  9. 8.5 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Application (2021-2032)
  10. 8.6 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country
  11. 8.6.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021-2026)
  13. 8.6.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (2021-2032)
  2. 9.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2027-2032)
  5. 9.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2027-2032)
  9. 9.5 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country
  11. 9.6.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (2021-2032)
  2. 10.2 China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2032)
  3. 10.2.1 China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026)
  4. 10.2.2 China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2027-2032)
  5. 10.3 China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Type (2021-2032)
  6. 10.4 China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2032)
  7. 10.4.1 China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026)
  8. 10.4.2 China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2027-2032)
  9. 10.5 China Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (2021-2032)
  2. 11.2 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2027-2032)
  5. 11.3 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2027-2032)
  9. 11.5 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country
  11. 11.6.1 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (2021-2032)
  2. 12.2 SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country
  11. 12.6.1 SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst